Phase II study of nimotuzumab (TheraCim‐hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma
Head & Neck2021Vol. 43(5), pp. 1641–1651
Citations Over TimeTop 13% of 2021 papers
Mei‐Kim Ang, Jose Enrique Montoya, Ekkasit Tharavichitkul, Cindy Lim, Terence Tan, Lan Ying Wang, Joseph Wee, Yoke Lim Soong, Kam‐Weng Fong, Quan Sing Ng, Daniel Shao‐Weng Tan, Chee‐Keong Toh, Eng‐Huat Tan, Wan‐Teck Lim
Abstract
The combination of nimotuzumab with cisplatin and radiotherapy was safe and achieved high response rates in HNSCC.
Related Papers
- → Phase II study of nimotuzumab (TheraCim‐hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma(2021)14 cited
- → Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, as monotherapy in patients with locally advanced or metastatic pancreatic cancer (PC)(2006)8 cited
- → Post hoc analysis of a randomized controlled trial comparing concurrent chemoradiation with cisplatin versus nimotuzumab-cisplatin, focusing on acute oral mucositis(2021)1 cited
- Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases(2020)
- → Nimotuzumab in the treatment of solid tumors(2013)